– USA, NJ – Outlook Therapeutics, Inc. (NASDAQ: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the appointments of Prof. Dr. Gerd Auffarth and Julian Gangolli to its Board of Directors.
“We are incredibly pleased to add individuals of Dr. Auffarth’s and Mr. Gangolli’s caliber to the Outlook Therapeutics Board of Directors,” said Lawrence A. Kenyon, President, CEO and CFO.
He added: “We believe that the significant R&D and clinical leadership and the knowledge of the ophthalmology space that Dr. Auffarth brings, as well as the deep commercialization expertise, including therapeutics for retinal diseases, that Mr. Gangolli adds will be invaluable as we advance our ongoing registration clinical trials for ONS-5010 / LYTENAVA (bevacizumab-vikg) towards commercialization.”
About Prof. Dr. Auffarth
Prof. Dr. Auffarth is an internationally recognized ophthalmologist in the area of research and development as well as clinical care for patients. He currently serves as the Medical Director of Heidelberg University Eye Clinic. Prior to his appointment as Medical Director in 2011, he worked as a senior physician at the University Eye Clinic. He currently serves as the Director of the International Vision Correction Research Center (IVCRC) and the David J. Apple Laboratory for Ocular Pathology, which he has established in the University Eye Clinic and which are recognized worldwide in the field of implant and biomaterial research. He is a board member of the German (General Secretary) and the European Society for Cataract and Refractive Surgery and is considered one of the most experienced surgeons in cataract and corneal surgery. As a co-founder of the Lions cornea bank in Heidelberg at the Heidelberg University Eye Clinic, Prof. Dr. Auffarth continued to advance transplant surgery (the human cornea) and innovative research areas at the Heidelberg site. In 2004 he was appointed Vice Chairman and Deputy Director of the Heidelberg Department of Ophthalmology; he was awarded Extraordinary Professorship in the Medical Faculty of the University of Heidelberg in May 2005.
About Julian Gangolli
Julian Gangolli is a leader in commercialization with a well-established track record and experience, having served as President of the North American Pharmaceutical division of Allergan, Inc. for 11 years where he was a member of the Executive Committee of Allergan and was responsible for a 1,400-person commercial operation with sales exceeding $3.8 billion in 2014.
Mr. Gangolli most recently served as President, North America of Greenwich Biosciences, a GW Pharmaceuticals PLC (NASDAQ: GWPH) Company, where he was responsible for building out the U.S. commercial infrastructure and spearheading the launch of its lead therapeutic product Epidiolex. Prior to that, Mr. Gangolli joined Allergan in 1998 and was a senior member of the management team that transformed the company into one of the leading specialty pharmaceutical companies in the United States. As a member of the Allergan Executive Committee, he was part of the select team that executed the sale of Allergan to Actavis in 2015.
In addition to joining the Outlook Board of Directors, Mr. Gangolli currently serves as a Director on the Board of two publicly traded pharmaceutical companies: Revance Therapeutics (NASDAQ: RVNC) and Krystal Biotech (NASDAQ: KRYS).
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, diabetic macular edema and branch retinal vein occlusion. If ONS-5010, its investigational ophthalmic formulation of bevacizumab, is approved, Outlook Therapeutics expects to commercialize it as the first and only approved ophthalmic formulation of bevacizumab for use in treating approved retinal diseases in the United States, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
For more information: https://outlooktherapeutics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
